Actively Recruiting
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Led by Revolution Medicines, Inc. · Updated on 2025-08-28
604
Participants Needed
17
Research Sites
190 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
CONDITIONS
Official Title
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation
- Received and progressed or been intolerant to prior standard therapy appropriate for tumor type and stage
- ECOG performance status 0 or 1
- Adequate organ function
You will not qualify if you...
- Primary central nervous system (CNS) tumors
- Known or suspected leptomeningeal or active brain metastases or spinal cord compression
- Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
- Previous treatment with investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or any direct RAS-targeted therapy (e.g., degraders and inhibitors)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
University of California, Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817
Actively Recruiting
2
Smilow Cancer Hospital (Yale University)
New Haven, Connecticut, United States, 06511
Actively Recruiting
3
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
4
Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612
Actively Recruiting
5
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Actively Recruiting
6
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
7
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
8
NYU Langone
New York, New York, United States, 10016
Actively Recruiting
9
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
10
Duke Cancer Center
Durham, North Carolina, United States, 27710
Actively Recruiting
11
Carolina BioOncology Institute
Huntersville, North Carolina, United States, 28078
Actively Recruiting
12
The Christ Hospital
Cincinnati, Ohio, United States, 45219
Actively Recruiting
13
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
14
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas, United States, 75230
Actively Recruiting
15
University of Texas, MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
16
START
San Antonio, Texas, United States, 78229
Actively Recruiting
17
NEXT Oncology Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
Research Team
R
Revolution Medicines, Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here